Rezalut pro

Quick links to important sections

Rezalut pro

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rezalut pro

Property Description
Active Ingredient Essential Phospholipids (Polyenylphosphatidylcholine)
Form Soft Gelatin Capsules (Oral)
Pharmacological Class Hepatoprotective Agent, Lipotropic Agent
Common Domain Supporting cellular membrane integrity
Origin Natural (Derived from Soybeans)

What Type of Medicine is Rezalut pro?

Rezalut pro is a specific pharmaceutical preparation classified primarily as a hepatoprotective agent and secondarily as a lipotropic agent. Its pharmacological identity centers on providing structural components for cellular health. The preparation is intended for oral administration and is supplied in the dosage form of soft gelatin capsules. This agent is utilized for supporting the health and function of the liver through the action of phospholipid components.

Composition: Essential Phospholipids and Natural Origin

The formulation contains a single active ingredient: a highly purified extract of Essential Phospholipids, namely polyenylphosphatidylcholine (PPC). This compound is of natural origin, derived from the soybean plant (Glycine max), providing a substance that is structurally congruent with endogenous body phospholipids. The product is manufactured to ensure a high, standardized concentration of the active Phosphatidylcholine fraction, including the critical 1,2-dilinoleoylphosphatidylcholine (DLPC) molecule. These phospholipids serve as fundamental structural components in supporting membrane fluidity and function.

General Purpose: Supporting Cellular Structure and Function

The general purpose of the medicine is to promote the structural integrity of the lipid bilayer within cell membranes. The Essential Phospholipids act by integrating directly into compromised areas of the cell wall, contributing to its stabilization and function. This action facilitates the maintenance of healthy cellular structures, thus supporting efficient function and stable transport processes across cell barriers, which is necessary for the functional capacity of metabolically active organs.

What side effects are possible with Rezalut pro?

Possible side effects and safety information

Regulatory documents classify the potential adverse reactions for Essential Phospholipids (Polyenylphosphatidylcholine) based on the body systems involved, focusing primarily on the gastrointestinal tract and the immune system. The overall frequency for most documented effects is often categorized as Not Known due to the nature of post-marketing reporting.


Adverse Reaction Scope

The most frequently cited potential adverse reactions are generally mild and non-serious, affecting two main System-Organ Classes:

  • Gastrointestinal Disorders: These effects include non-serious complaints such as stomach upset, nausea, and diarrhea.
  • Skin and Subcutaneous Tissue Disorders: Reactions may include various signs of hypersensitivity, such as skin rash, pruritus (itching), or hives (urticaria).

Serious Adverse Reactions and Safety Restrictions

The most critical safety statement in regulatory information concerns hypersensitivity. Severe adverse reactions, particularly severe allergic reactions, are a potential risk and are explicitly noted in the product's documentation.

  • Contraindications: Due to its natural origin (containing soybean oil), the product is strictly contraindicated in individuals with known hypersensitivity to soy products (e.g., soybean oil, soybean protein) or related allergens such as peanut or egg protein.
  • Use in Specific Populations: Official regulatory texts advise caution and do not recommend use during pregnancy or lactation due to the lack of sufficient human safety data in these specific populations.
  • Drug Interaction Safety Note: A high-level safety note in regulatory information indicates that an interaction with certain anticoagulant medications (such as Coumarin derivatives) cannot be ruled out, representing a necessary consideration for safety monitoring.

This structure ensures the medicine's safety profile is communicated by highlighting established risks and regulatory constraints, without offering clinical guidance or interpretation.

Overdose and Emergency Response

The official regulatory documents provide specific information regarding overdose for Rezalut pro (Essential Phospholipids). The profile is characterized by minimal documented risk, as no known cases of overdose or acute intoxication have been formally reported with the oral capsule formulation. This key regulatory statement establishes the context for managing excessive intake.

Domain Official Regulatory Statement
Overdose Presentation Manifestations are strictly limited to the potential for an increased intensity of known undesirable effects. These primarily involve gastrointestinal disorders, such as stomach discomfort, diarrhea, or soft stools.
Mandated Action If side effects occur with greater intensity than typically experienced, the regulator-mandated action is to immediately inform a doctor or other qualified healthcare professional for assessment.
Antidote Status No specific antidote is known to exist for intoxication with the active ingredient, confirming that management relies on addressing symptoms.

When to Seek Urgent Medical Help

Urgent medical consultation is required when the known symptom profile becomes significantly more pronounced due to suspected excessive intake. The regulatory guidance establishes that immediate medical assessment must be sought if any existing side effects are experienced with a level of severity or intensity that is unusual or pronounced. Treatment, if initiated, is focused on symptomatic and supportive measures, as no specific reversal agent is available. There are no population-based overdose considerations explicitly documented in the official prescribing information.

Therapeutic Uses of Rezalut pro

Rezalut pro is a prescription medication indicated for the specialized management of Non-Alcoholic Steatohepatitis (NASH) in adults. Specifically, this therapy is used in patients who have moderate to advanced liver scarring, known as fibrosis, but have not yet progressed to cirrhosis. The primary objective of the medication is intended to support liver health and function by addressing the underlying inflammation and damage associated with NASH.

The therapy can offer a means to slow the progression of liver damage, which is vital in managing this chronic condition. Rezalut pro may contribute to a resolution of NASH symptoms without the worsening of liver scarring in some individuals. Common clinical scenarios for its use include managing progressive chronic liver disease, addressing inflammation, and supporting long-term liver structure.

Quick Fact: Support for managing NASH-related inflammation and fibrosis.

Regulatory References

  1. NIH MedlinePlus guidance on fatty liver disease

Eligibility and Restrictions for Use

Rezalut pro’s eligibility for use is strictly defined by regulatory authorities and is generally confined to adults who do not possess any absolute contraindications. The official prescribing information establishes mandatory exclusions based on allergy, age, and specific pre-existing conditions.

Population Status Official Regulatory Wording
Contraindicated (Must Not Use) Patients with known hypersensitivity to the active ingredient (Polyenylphosphatidylcholine) or any excipients. Also includes those with known allergy to soya-bean, egg, or peanut products (due to the product's origin).
Absolute Exclusion Patients with severe disorders of lipid metabolism, particularly those involving severe hypertriglyceridemia, are officially excluded from use.
Conditional & Age Restrictions Eligibility Status
Children Under 12 Years Not Recommended. Regulatory agencies state that use is not established due to insufficient data for this age group.
Pregnancy and Lactation Not Recommended. Use is restricted because results from investigations during these physiological states are insufficient to confirm definitive safety.
Chronic Hepatitis Use is conditional, justified only when subjective well-being becomes manifest during the course of therapy.

This profile emphasizes mandatory non-eligibility based on allergies and metabolic restrictions, and sets clear limits where safety data is lacking, confining use to the established adult patient group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Essential Phospholipids (Rezalut pro) is characterized by a specific pharmacodynamic interaction and an overall absence of documented effects in common pharmacokinetic pathways.

Documented Drug-Drug Interactions

Interaction Type Interacting Substance / Category Official Regulatory Statement
Pharmacodynamic Anticoagulants (Coumarin derivatives) Co-administration may potentiate the effects of these blood-thinning substances, officially increasing the documented risk of bleeding in the patient.
Pharmacokinetic CYP/Transporter Substrates Regulatory documents do not contain official statements detailing clinically relevant metabolic or drug-transporter-mediated interactions.
Contraindications None No specific medicinal products are formally classified as strictly contraindicated for use with Essential Phospholipids.

Interaction Constraints and Monitoring

The formally documented potentiation of anticoagulant activity establishes a clear constraint for concurrent use: intensified monitoring of coagulation parameters, such as the International Normalized Ratio (INR), is mandatory when Rezalut pro is co-administered with coumarin derivatives. This procedural requirement is intended to mitigate the risk associated with enhanced anticoagulant effects.

Regulatory prescribing information also indicates that there are no documented interactions requiring separation of administration or dose adjustments due to metabolic effects. Furthermore, the official label does not specify any clinically relevant interactions with food, alcohol, or common herbal products.

Mechanism of Action

How Rezalut Pro Works

Targeting an Intracellular Enzyme: PDE4 Inhibition

Rezalut pro exerts its primary action by functioning as a highly selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). This enzyme is present in various immune and inflammatory cells throughout the body. By specifically binding to and inhibiting PDE4, the drug prevents the breakdown of the essential intracellular messenger molecule, cyclic AMP (cAMP).


Modulating the Signaling Cascade: Cyclic AMP Regulation

The subsequent accumulation of intracellular cAMP directly modulates activity within the immune cells. Elevated cAMP levels initiate a cascade that shifts the cell's function, specifically affecting the pathways that govern the production of chemical mediators. This modulation leads to the downregulation of certain pro-inflammatory substances, such as TNF-alpha and IL-17.


Physiological Consequence: Dampening the Inflammatory Profile

The drug’s effect on cellular signaling translates into a systemic modulation of the inflammatory mediator profile. By altering the balance of these substances (increasing anti-inflammatory and decreasing pro-inflammatory outputs), the mechanism reduces the production and release of inflammatory mediators, resulting in a systemic shift in the inflammatory profile.

Dosage and Administration Information

How Rezalut pro is Used: Administration Guidelines

Rezalut pro is administered according to a standardized oral regimen involving a specific method, frequency, and dose. The medicinal product contains Essential Phospholipids and is supplied in hard gelatin capsules for ingestion.

Administration Scope Detail
Route of Administration The primary approved route is oral via capsule. Intravenous administration may be used in certain clinical settings to initiate treatment.
Standard Dosing Schedule The established therapeutic regimen requires a total daily intake of 1800 mg of Essential Phospholipids. This dose is typically achieved by administering two 300 mg capsules per dose.
Frequency and Timing The full daily amount is delivered in a divided regimen of three times daily (TID). Each dose must be taken with meals to facilitate the optimal absorption of the lipophilic active ingredient.
Preparation and Method The capsules must be swallowed whole and unchewed, accompanied by an adequate amount of liquid.
Age-Group Rules The standardized regimen is defined for adolescents (age 12 and older) and adults. Use in children under 12 years of age is generally restricted.
Course Duration The overall duration of use is generally not limited in standard guidelines, reflecting its role in long-term supportive management, though typical clinical courses may range from 3 to 6 months.

This structure defines the standardized procedural requirements for using the medicine, establishing the precise dose, frequency, and context necessary for administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Rezalut pro

## Evidence for Use in Non-Alcoholic Steatohepatitis (NASH) and NAFLD

Research has explored the use of Essential Phospholipids (the active component in Rezalut pro) in individuals with liver conditions, including Non-Alcoholic Steatohepatitis (NASH) and the broader condition of Non-Alcoholic Fatty Liver Disease (NAFLD). Research protocols examined the compound in adult populations facing these chronic liver challenges.

The studies focused on outcomes related to systemic or functional imbalance in the liver. Research explored changes in biochemical markers, such as liver enzyme levels (e.g., ALT and AST), and monitored non-invasive imaging parameters of liver health, including measurements of steatosis and stiffness. Histological measures were evaluated in studies examining changes in fibrosis stage and NASH activity. Findings from these trials report how symptoms evolved in the observed populations over the duration of the research period.


## What Types of Studies Support Regulatory Review

The available evidence was observed in a variety of research designs. This includes numerous small-scale Randomized Controlled Trials (RCTs) and various large, prospective observational studies that collect data from real-world clinical settings, often spanning multiple centers.

Systematic reviews and meta-analyses of the available research contribute to the broader evidence landscape and summarize the available data. Because the sample sizes were modest in some of the controlled trials, regulatory reviews consider the combination of these controlled studies with the findings from large real-world cohorts.


## Long-Term Research and Durability of Follow-Up

Research examined the response over defined time intervals, with the majority of published trials reporting observations over short-to-intermediate periods, often ranging from 12 weeks up to six months. Within these timeframes, the studies report how symptoms evolved in the observed populations and measured changes in liver markers.

Scientific bodies note that long-term effects are not fully established with the currently available data. The need for specialized long-term controlled clinical trials is documented to assess the durability of observations. There is limited information for long-term outcomes that fully characterize sustained health status or the progression of liver disease over multiple years.


## Research in Specific Patient Groups

Research was evaluated in specific populations, primarily adults diagnosed with NAFLD or NASH. Studies frequently included individuals who presented with co-existing metabolic comorbidities, such as Type 2 Diabetes, obesity, and hyperlipidemia. This inclusion reflects the close association between these conditions and the study populations.

The results apply only to the populations studied, meaning data for certain groups remain insufficient. For instance, dedicated, large-scale studies focusing exclusively on individuals without any metabolic comorbidities or in pediatric populations are less common in the currently published evidence base.


## What Remains Unclear or Under Study

The research base highlights key areas where certainty remains low and where further research is documented as necessary. The evidence quality varies across studies, and the reliance on surrogate endpoints like enzyme changes and imaging results means that a direct understanding of long-term health outcomes is not fully established.

Comparative evidence is lacking, which limits the understanding of study findings relative to other interventions for NASH and NAFLD. Research provides context but not individual predictions, and the need for further studies with larger sample sizes and extended follow-up durations is a documented limitation in the evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Rezalut pro (FAQ)


Q: Is Rezalut pro the same as other medications used for the same purpose?

Official regulatory documents classify the active ingredient, Essential Phospholipids, as a hepatoprotective agent, which is a therapeutic class used for liver support. Its mechanism is described as involving the direct incorporation of phospholipids into cell membranes, which official sources indicate supports structural integrity and function.


Q: Does Rezalut pro have a serious or high-risk safety warning from regulators?

Regulatory documents establish strict constraints regarding safety. They list hypersensitivity to soy, peanut, or egg products as a strict contraindication (must not be used). Official information also requires intensified monitoring when the medicine is used alongside certain blood-thinning medicines, due to the documented risk of potentiated bleeding. This monitoring is required to mitigate the risk associated with potentiated bleeding.


Q: What does the patient information leaflet say about alcohol use with Rezalut pro?

Regulatory information indicates that there are no documented clinically relevant drug-alcohol interactions. However, because the product is intended for conditions involving the liver, official sources state that alcohol consumption is generally discouraged due to its known adverse effects on liver health.


Q: Is it required to take Rezalut pro with food?

Official administration guidelines state that taking the doses with meals is a condition of use. This condition is necessary to ensure the optimal absorption of the active ingredient, which is a lipophilic (fat-soluble) substance.


Q: Does my age matter when a doctor decides to prescribe Rezalut pro?

Official information defines the standard regimen for adolescents (age 12 and older) and adults. While use is restricted below age 12 due to a lack of sufficient data, regulatory agencies do not typically impose specific age-related dose adjustments or restrictions for the elderly within the established adult population.


Q: What should I do if I forget to take my Rezalut pro dose?

Regulatory guidance for missed doses typically instructs patients to take the dose as soon as they remember. However, regulatory guidance explicitly states that a patient should not double the dose the next time it is due to compensate for the missed one.


Q: Is there a list of foods or drinks that should be avoided while using Rezalut pro?

Regulatory documents state there are no documented clinically relevant interactions with food or common herbal products. The product label does not specify any particular foods that must be avoided while using this medicine.


Q: Does Rezalut pro affect my ability to drive or operate machinery?

The absence of warnings in regulatory documentation indicates that no effect on driving or operating machinery has been formally observed or reported for the active ingredient.


Q: Does Rezalut pro require special blood tests while I'm taking it?

Official information requires the intensified monitoring of coagulation parameters, such as the International Normalized Ratio (INR), when the medicine is taken concurrently with coumarin anticoagulants. This is done to help manage the risk of increased bleeding.


Q: Is Rezalut pro known to cause long-term dependency or addiction?

Regulatory documents classify the active ingredient as a hepatoprotective agent and not a controlled substance. Dependency or addiction is not listed in the product’s official safety profile.


Q: What is the maximum duration of treatment that has been studied for Rezalut pro?

Regulatory-reviewed research often reports observations over short-to-intermediate periods, which typically range up to six months. However, the overall duration of use is generally not limited in official documents, reflecting its role in long-term supportive management.


Q: Can Rezalut pro cause unexpected changes in mood or behavior?

Regulatory adverse reaction profiles for the active ingredient do not commonly list mood or behavioral changes (psychiatric disorders) as documented side effects.


Q: Is there a specific time of day that is best described for taking Rezalut pro?

Administration guidelines define the frequency as three times daily (TID) and specify that each dose must be taken with meals. No specific emphasis on morning or evening is typically given beyond adherence to the meal schedule.


Q: Can Rezalut pro affect my blood pressure?

Regulatory adverse reaction listings for the active ingredient do not commonly include changes to blood pressure, such as hypertension (high blood pressure) or hypotension (low blood pressure), as reported side effects.


Q: What do regulators say about the long-term safety of Rezalut pro?

Official regulatory reviews explicitly note that the long-term effects of the medicine are not fully established with currently available data. The need for long-term controlled clinical trials is documented by regulatory reviews to address this limitation.


Q: Can taking Rezalut pro make my other existing medical condition worse?

Regulatory documents list certain contraindications, such as severe disorders of lipid metabolism, which indicate that using the product in the presence of these specific conditions can increase the risk of adverse outcomes. Contraindications define populations where use is strictly restricted.


Q: Does Rezalut pro interact with common lab tests?

Official patient safety information for similar lipid-based products indicates that the medicine's lipid content may interfere with the results of certain laboratory tests if blood is drawn too soon after taking a dose.


Q: Can Rezalut pro cause weight change?

Weight gain or weight loss is not commonly listed as an adverse reaction for the active ingredient in official regulatory documents.


Q: Are there specific times when a dose of Rezalut pro should be avoided?

Official instructions define the required schedule as three times daily with meals. No specific times for avoiding a dose are typically defined outside of the required administration schedule.


Q: How is the elimination of Rezalut pro from the body described?

The active ingredient, Essential Phospholipids, is described as an endogenous-like substance. It undergoes hydrolysis (breakdown) in the gastrointestinal tract, is then absorbed, and is incorporated directly into the body's pool of phospholipids.


Q: Can Rezalut pro be taken at the same time as cold and flu medicine?

Regulatory documents state there are no documented clinically relevant metabolic or drug-transporter-mediated interactions that would require separating the administration of Rezalut pro from most other medicines.


Q: Are there any specific lifestyle factors mentioned that might affect Rezalut pro?

Regulatory-reviewed research acknowledges that the product is intended as supportive management for chronic conditions often associated with metabolic comorbidities, such as obesity and diabetes. This implicitly suggests that healthy lifestyle management is part of the overall therapeutic context.


Q: Why do official documents say Rezalut pro should only be used under medical supervision?

Official documents require medical supervision due to the product's use in chronic, complex liver diseases, the existence of specific contraindications, and the need for monitoring when co-administered with other medicines, such as anticoagulants.


Q: What is the recommended approach for starting treatment with Rezalut pro?

The starting approach is defined by the official standardized oral regimen, which specifies the required dose, frequency, and timing (with meals) as outlined in the administration guidelines.


Q: Does Rezalut pro carry a risk of overdose and what are the symptoms?

Regulatory documentation indicates that symptoms of an overdose would likely be an exaggeration of the known common side effects, such as gastrointestinal disturbances.


Q: Do studies show a difference in effect between different doses of Rezalut pro?

The regulatory evidence relies on studies using the standardized therapeutic regimen, and official documents do not typically contain comparative data on the effect of different dose strengths.


Q: Does Rezalut pro interact with herbal supplements?

Regulatory documents state there are no documented clinically relevant interactions with common herbal products.

How should Rezalut pro be stored and disposed of?

How to Store and Dispose of Rezalut pro?

The storage and disposal of Rezalut pro soft gelatin capsules must strictly follow the conditions defined in the official regulatory labeling.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store below 25 C or 30 C (check specific regional label).
Environment Protect from moisture and light; do not freeze the medicine.
Packaging Keep the capsules in the original blister and outer carton until the time of use.
Safety Keep the medicine out of the sight and reach of children.
Stability Do not use the medicine after the expiration date printed on the package.

Disposal Instructions

Official disposal rules require that unused or expired Rezalut pro must not be thrown away via household waste or flushed down the toilet. The medicine must be discarded through approved pharmaceutical take-back programs or by asking a pharmacist for guidance on local collection points. This process ensures proper destruction and minimizes environmental impact.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rezalut pro found in:

A-Z Index: